GeneTex
Hsinchu
About GeneTex
In early 1997, GeneTex, Inc. started operations in San Antonio, Texas. GeneTex was founded by three internationally renowned scientists with recognized expertise in clinical oncology, cancer biology and infectious diseases. Based on their breadth of experience and research interests, the company's initial focus was breast cancer biology and prognostic marker research. This evolved to incorporate a comprehensive portfolio of immunological reagents used by scientists studying the underlying mechanisms common to many forms of cancer. GeneTex’s product portfolio has expanded to cover research areas including cancer, cell biology, epigenetics, immunology, infectious disease, metabolism, neuroscience, signal transduction, stem cell development and zebrafish biology. In 2009, GeneTex relocated to Irvine, California to be more centrally located to the biotechnology hub in Southern California, which coincided with the construction of a state-of-the-art high-capacity manufacturing facility. By 2011, GeneTex had grown to become a multinational organization and one of the largest antibody manufacturers with a global distribution network. GeneTex is proud to offer the highest quality antibody reagents supported by extensive research, development, and validation.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $4.3M
- Last round: Series Unknown (Mar 2012)
- Website: genetex.com
- Phone: 2106778843
Industries & Categories
Biotechnology, Life Science, Neuroscience
Social Profiles
Canonical: https://fsome.com/organization/genetex-2425999 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.